OLN324 for macular degeneration

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Sep 2026: Trial registered, NCT07816315

The trials

NCT07816315: Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)

State
Not started
Phase
Phase 3
People
500 planned
Started
15 Oct 2026
Primary completion
15 Dec 2028
Arms
OLN324
Results
None posted
  1. 11 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.